Supervised classification of 1H-MRS-visible frontal cortex metabolites differentiated progressive from relapsing-remitting multiple sclerosis with 84% sensitivity and 74% specificity.
Cross-Sectional (n=68)
No
Does 1H MRS of frontal cortex metabolites accurately differentiate multiple sclerosis status and phenotypes?
1H MRS of frontal cortex metabolites can differentiate progressive MS from controls and relapsing MS phenotypes, offering a potential auxiliary diagnostic tool.
Effect estimate: AUROC 0.86
Abstract Multiple sclerosis (MS) is a heterogeneous autoimmune disease for which diagnosis continues to rely on subjective clinical judgment over a battery of tests. Proton magnetic resonance spectroscopy ( 1 H MRS) enables the noninvasive in vivo detection of multiple small-molecule metabolites and is therefore in principle a promising means of gathering information sufficient for multiple sclerosis diagnosis and subtype classification. Here we show that supervised classification using 1 H-MRS-visible normal-appearing frontal cortex small-molecule metabolites alone can indeed differentiate individuals with progressive MS from control (held-out validation sensitivity 79% and specificity 68%), as well as between relapsing and progressive MS phenotypes (held-out validation sensitivity 84% and specificity 74%). Post hoc assessment demonstrated the disproportionate contributions of glutamate and glutamine to identifying MS status and phenotype, respectively. Our finding establishes 1 H MRS as a viable means of characterizing progressive multiple sclerosis disease status and paves the way for continued refinement of this method as an auxiliary or mainstay of multiple sclerosis diagnostics.
Swanberg et al. (2022) conducted a cross-sectional in Multiple Sclerosis (n=68). Proton magnetic resonance spectroscopy (1H MRS) with multivariate classification vs. Healthy controls and relapsing-remitting multiple sclerosis was evaluated on Differentiation between progressive and relapsing-remitting multiple sclerosis (Quadratic Discriminant Analysis model) (AUROC 0.86). Supervised classification of 1H-MRS-visible frontal cortex metabolites differentiated progressive from relapsing-remitting multiple sclerosis with 84% sensitivity and 74% specificity.